Collaborators / Investors
14K+
Happy Customer
27K+
Product Sold
20+
Years Experience
Investors Welcome
Orinove Inc., is actively seeking investors and partners
Orinove Inc., is actively seeking investors for Phase 2 trials in oncology and IPF, and other serious diseases with the lead compound, ORIN1001.
Collaborators
Dr. Mothaffar Rimawi
Medical Director of the Lester and Sue Smith Breast Center; Baylor College of Medicine, Houston Texas
Dr. Xi Chen
Professor, Baylor College of Medicine, Houston Texas
Dr. Afshin Somali
Professor, University of Galway, Ireland
Dr. Fahri Saatclogui
Professor for Molecular and Cell Biology, University of Oslo, Norway
Dr. Timothy Blackwell
Professor, Vanderbilt University, Nashville, Tennessee
Dr. Kenneth Anderson
Dana Farber Canter; Program Director, Jerome Lipper Multiple Myeloma Center; Kraft Family Professor of Medicine, Harvard Medical School
Dr. Eric Chevet
Research Director, French National Institute for Health and Medical Research (Inserm)
KOLs and Advisors
- Oncology Study PI and KOL: Dr. Mothaffar Rimawi, Baylor College of Medicine, Houston Texas
- Professor, Department of Medicine, Section of Hematology and Oncology
- Executive Medical Director & Associate Director of Clinical Affairs
- Dan L Duncan Comprehensive Cancer Center
- Co-Leader, Breast Cancer Program, Dan L Duncan Comprehensive Cancer Center
- Chief, Oncology Service Line, St Luke’s Health
- IPF KOL and Advisor: Dr Timothy Blackwell, Vanderbilt University, Nashville Tennessee
- Professor of Medicine, Division Allergy, Pulmonary, and Critical Care Medicine
- Director, Division of Allergy, Pulmonary & Critical Care Medicine and the Center for Lung Research
- Rudy W. Jacobson Chair in Pulmonary Medicine, Professor of Medicine and Cell and Developmental Biology
Orinove Consultants and Collaborators
